Appeals court splits over embryonic stem cells

gavel

The three-judge panel on a federal appeals court considering whether to overturn a ban on federal funding of embryonic stem cell research revealed a split during a hearing yesterday.

President Barack Obama’s administration is appealing a lower court decision banning federal funding of the research. During yesterday’s hearing at the U.S. Court of Appeals for the District of Columbia Circuit, two of the judges questioned the U.S. Justice Dept.’s arguments that the ban would do irreparable harm to the public interest, while a third seemed more sympathetic.

Judge Royce Lamberth of the U.S. District Court for the District of Columbia had ruled that federal funds could not be used for the the research, derailing scores of projects looking into the causes of diseases like Parkinson’s, Alzheimer’s and cystic fibrosis. Obama had sought to restore stem cell research funding from constraints imposed under the Bush administration, but Lamberth ruled that the policy violated the Dickey-Wicker Amendment, aimed at stopping the destruction of human embryos.

But Dickey-Wicker proved to be a sticky wicket for both plaintiffs and defendants when the appeals court issued a temporary stay of the Lamberth ruling.

Obama’s policy allowed the use of stem cell lines derived from frozen embryos from fertility treatments that were no longer needed and donated according to stringent ethical guidelines. The plaintiffs in the lawsuit, James Sherley and Theresa Deisher, argued that the Obama policy violated the Dickey-Wicker rules.

Beth Brinkmann, a Justice Dept. lawyer, argued that the ban would be a waste of the $64 million that’s already been spent on 24 research projects at the National Institutes of Health, according to news reports. Thomas Hungar, an attorney for the plaintiffs, called that argument speculation and maintained that no injury is imminent or irreversible.

Judge Thomas Griffith, a George W. Bush appointee, appeared to be the most skeptical of the government’s argument, saying that the judges are not hearing the case to decide the wisdom of government policy but to judge whether the research violates the Dickey-Wicker amendment.

“All $64 million is completely ruined?” Griffith asked. “They don’t keep lab notebooks?”

There are notes, Brinkmann said, but “it would be a setback for the field. Biological material would be destroyed.”

Judge Brett Kavanaugh, another George W. Bush appointee, called the government’s position “odd” and “internally inconsistent” but said it might be best to defer to the government’s arguments because of the ambiguity of the Dickey-Wicker statute.

Clinton appointee Judge Judith Rogers said that even a temporary halt to the funding could damage public interest represented by the research.

The Justice Dept. previously argued that Congress never intended for the Dickey-Wicker rules to bar all embryonic stem cell research.

"The National Institutes of Health has funded research using embryonic stem cells since 2002, and has not interpreted the Amendment to bar such grants,” according to court documents. "Fully aware of NIH practice, Congress has used the same language in reenacting the funding limitation, and has repeatedly made clear that NIH’s practice is consistent with the statute. Indeed, the relevant Committee Report for the 2010 appropriations bill, enacted after issuance of the current NIH guidelines, noted that the bill ‘should not be construed to limit Federal support for research involving human embryonic stem cells carried out in accordance with policy outlined by the President.’"

That’s because research using stem cell lines already in existence doesn’t involve the destruction of the embryos, the DOJ argued.

"The bar posited by plaintiffs and the district court has never existed," according to the documents. "[R]esearch using embryonic stem cells is not ‘research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death.’ Plaintiffs insist that this consistent interpretation reflects a ‘warped reading of the term "research,"’ which should be understood to mean a ‘systematic investigation.’ Referring to scientific research projects as ‘systematic investigations’ adds nothing to plaintiffs’ argument and does not expand research funded by NIH to include antecedent acts that were not funded by NIH."

Furthermore, the Justice Dept. argued, barring federal funding of the research will have a catastrophic impact on medical research.

"Disruption of ongoing research will result in irreparable setbacks and, in many cases, may destroy a project altogether. In contrast, the two plaintiff scientists identify no imminent irreparable injury," according to the department.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply